Quarterly report
Open the filing on sec.gov
Acurx Pharmaceuticals, Inc. (ACXP)
Nasdaq: ACXP · Pharmaceutical Preparations · Staten Island, NY · filing with the SEC since 2018
The companyfiscal 2025, as filed
Revenuen/a
Net income-$8.0M+43.5%
Earnings per share$-5.32+69.5%
Operating cash flow-$6.8M+34.6%
Cash$7.6M+103.8%
Debtn/a
Shareholders’ equity$5.3M+756.5%
Shares, diluted1,498,793+85.5%
Return on equity-151.2%
The recordfrom its filings
Filings in 202642
Newest filingNov 12 · 10-Q
Annual reportMar 12, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted34
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Net income -$8.1MCash from operations -$6.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.